AMOUNT OF PREOPERATIVE ENDOMETRIAL TISSUE 43 2 Table S1. Baseline characteristics of patients diagnosed with postoperative NEEC histology and divided by the NEEC subgroups NEEC total (n=34) Serous (n=14) Clear cell (n=8) Carcinosarcoma (n=7) Heterogenous (serous + clear cell) (n=5) Age (years) 65.5 (47.0-88.0) 64.0 (51.0-82.0) 65.0 (47.0-81.0) 69.0 (56.0-74.0) 72.0 (61.0-88.0) BMI ((kg/m2) 27.0 (18.4-41.5) 27.3 (18.4-37.8) 24.6 (21.2-33.6) 27.0 (22.0-41.1) 29.3 (20.4-41.5) Preoperative grade Premalignant† 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 4 (11.8) 3 (21.4) 0 (0.0) 1 (14.3) 0 (0.0) 3 14 (41.2) 5 (35.7) 3 (37.5) 2 (28.6) 4 (80.0) NEEC 16 (47.0) 6 (42.9) 5 (62.5) 4 (57.1) 1 (20.0) FIGO stage surgical I 13 (38.2) 6 (42.9) 2 (25.0) 4 (57.1) 1 (20.0) II 6 (17.6) 0 (0.0) 2 (25.0) 2 (28.6) 2 (40.0) III 11 (32.4) 6 (42.9) 3 (37.5) 1 (14.3) 1 (20.0) IV 4 (11.8) 2 (14.2) 1 (12.5) 0 (0.0) 1 (20.0) Positive nodes No 15 (44.1) 6 (42.9) 2 (28.6) 6 (85.7) 1 (50.0) Pelvic 6 (17.6) 3 (21.4) 2 (28.6) 0 (0.0) 1 (50.0) Para-aortic 5 (14.7) 3 (21.4) 2 (28.6) 0 (0.0) 0 (0.0) Both 2 (5.9) 0 (0.0) 1 (14.3) 1 (14.3) 0 (0.0) Adjuvant treatment No 12 (35.3) 3 (21.4) 3 (37.5) 3 (37.5) 3 (60.0) Radiotherapy 12 (35.3) 6 (42.9) 2 (25.0) 2 (25.0) 1 (20.0) Chemotherapy 7 (20.6) 4 (28.6) 3 (37.5) 3 (37.5) 0 (0.0) Chemoradiotherapy 3 (8.8) 1 (7.1) 0 (0.0) 0 (0.0) 1 (20.0) Data is presented in number (%) and median (range) Abbreviations: NEEC, non-endometroid endometrial cancer; BMI, Body Mass Index; FIGO, International Federation of Gynecology and Obstetrics †including simple or complex hyperplasia, with or without atypia.
RkJQdWJsaXNoZXIy MTk4NDMw